重组人干扰素α-2b喷雾剂在治疗儿童水痘中作用的研究

Effect of recombinant human interferon alpha-2b spray for varicella in children

目的探讨重组人干扰素α-2b喷雾剂在治疗儿童水痘的临床疗效。方法选择2016年9月至2017年5月在邯郸市第一医院门诊就诊的80例水痘患儿,其中男性38例,女性42例;年龄3~13岁,平均年龄6.77岁;病程(4.41±1.40)d。按照随机数字表法分为2组,每组各40例。观察组40例(男性18例,女性22例),予以盐酸伐昔洛韦颗粒剂联合局部外用重组人干扰素α-2b喷雾剂(每处1~2喷,每天4次)进行治疗;对照组40例(男性20例,女性20例),盐酸伐昔洛韦颗粒剂联合局部外用炉甘石洗剂进行治疗。两组患儿在观察治疗期间停用内服及其他外用药物,共治疗1个疗程(6 d),并于治疗结束后判定临床疗效,记录患儿皮损处瘙痒缓解时间、水疱结痂时间、全部脱痂自愈时间并对比数据进行分析。结果治疗1个疗程后,观察组总有效率优于对照组(87.5%vs 67.5%);两组比较,差异有统计学意义(χ~2=4.588,P<0.05)。瘙痒缓解时间两组差异无统计学意义(t=0.404,P>0.05)。观察组水疱结痂时间及全部脱痂自愈时间较对照组明显缩短[(3.05±1.14)d vs(4.06±1.07)d,(5.60±1.13)d vs(7.10±1.63)d];两组比较,差异有统计学意义(t=2.372、3.503,P<0.05)。观察组2例患儿出现轻度的刺激性咳嗽,未予处理,症状自行缓解。结论重组人干扰素α-2b喷雾剂治疗儿童水痘无明显不良反应,见效快,有效尽早降低疾病的传染性,值得临床推广应用。

Objective To investigate the effect of topical application of recombinant human interferon alpha-2 b spray for treatment of varicella in children. Methods From September 2016 to May 2017, a total of 80 children with varicella were enrolled, which included 38 males and 42 females, aged 3-13 years old with mean age of 6.77 years old, and course of dis-ease was（4.41 ± 1.40） days. All of them were divided into observation group（n = 40, 18 males and 22 females） and control group（n = 40, 20 males and 20 females） by random number tab. The observation group was given Valacyclovir hydrochloride gran-ules combined with recombinant human interferon α-2 b spray and control group was given Valacyclovir hydrochloride granules combined with calamine lotion. All of them were determined clinical efficacy after a course（6-day） of treatment, the time of pru-ritus relief, blister scab, scab healing were recorded and compared with the data. Results After a course of treatment, the total effective rate of observation group was better than that of control group（87.5 % vs 67.5 %）, the difference was statistically significant between 2 groups（χ~2= 4.588, P〈0.05）. There was no significant difference of pruritus relief between 2 groups（t = 0.404, P〉0.05）. The time of blister scab and scab healing of observation group were significantly shorter than the control group[（3.05 ± 1.14） days vs（4.06 ± 1.07） days,（5.60 ± 1.13） days vs（7.10 ± 1.63） days]; The difference was statistically significant between 2 groups（t = 2.372, t = 3.503, P〈0.05）. In observation group, 2 cases occurred mild irritation cough and relieved without any treatment. Conclusion It is demonstrated that recombinant human interferon alpha-2 b spray is no obvious adverse effects on children with varicella. It is effective in reducing infectivity as early as possible, so it is worthy of clini-cal application.